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The Human Genome Organization (HUGO) was initially established in 1988 to help
integrate international scientific genomic activity and to accelerate the diffusion of
knowledge from the efforts of the human genome project. Its founding President
was Victor McKusick. During the late 1980s and 1990s, HUGO organized lively gene
mapping meetings to accurately place genes on the genome as chromosomes were
being sequenced. With the completion of the Human Genome Project, HUGO went
through some transitions and self-reflection. In 2020, HUGO (which hosts a large
annual scientific meeting and comprises the renowned HUGO Gene Nomenclature
Committee [HGNC], responsible for naming genes, and an outstanding Ethics Com-
mittee) was merged with the Human Genome Variation Society (HGVS; which
defines the correct nomenclature for variation description) and the Human Variome
Project (HVP; championed by the late Richard Cotton) into a single organization that
is committed to assembling human genomic variation from all over the world. This con-
solidated effort, under a new Executive Board and seven focused committees, will
facilitate efficient and effective communication and action to bring the benefits of
increasing knowledge of genome diversity and biology to people all over the world.
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1 | IN THE BEGINNING
In 1988, as the Human Genome Project was getting under way, Nobel
laureate Sydney Brenner proposed the creation of an international
coordinating body to help integrate scientific genomic activity and
proposed the name HUGO, the Human Genome Organization. On
April 30, 1988, at a meeting at Cold Spring Harbor, the proposal was
endorsed and Victor McKusick was invited to be the founding Presi-
dent. By early September, a Founding Council had been assembled
comprising of 42 scientists from 17 countries, the majority of whom
met in Montreaux, Switzerland and elected Walter Bodmer, Jean
Dausset, and Kenichi Matsubara as HUGO Vice Presidents, John
Tooze as Secretary, and Walter Gilbert as Treasurer. Charles Cantor,
Malcolm Ferguson-Smith, Leroy Hood, Lennart Philipson and Frank
Ruddle served as executive committee members. A further 178 mem-
bers were also chosen, bringing the original membership of HUGO to
220 scientists, drawn from 23 countries. It was to be, in the words of
Norton Zinder, “a U.N. for the human genome” (Figure 1). Stylianos
Antonarakis (one of the co-authors of this article) was among the ini-
tial 220 scientists that comprised HUGO!
HUGO sought to be “international and interdisciplinary” with pur-
poses “to assist with the coordination of research on the human
genome, to foster collaboration, avoiding unnecessary duplication of
effort”; and also coordinate parallel studies in model organisms.
HUGO also aimed to facilitate the exchange of data and biomaterials
and encourage the spreading of related technologies. Finally, HUGO's
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purpose was also to inspire public debate and provide information
and advice on the scientific, ethical, social, legal, and commercial impli-
cations of the human genome projects.
Over the years, the HUGO offices have moved around from
country to country, starting from Switzerland, and then being moved
to the United States, United Kingdom, Japan, Singapore, and
F IGURE 1 HUGO membership in early 1989. Those scientists whose names are in bold and marked with an * are members of the founding
council. HUGO Members included: Bruce M. Alberts, USA; Richard Gelinas, USA; Peter L. Pearson*, The Netherlands; Philip Avner, France;
Walter Goad, USA; Elizabeth B. Robson*, UK; Bart G. Barrell, UK; Francois Gros, France; Leon E. Rosenberg, USA; Kare Berg, Norway; John
L. Hamerton, Canada; Joseph Sambrook, USA; Walter Bodmer*, UK; Tasuku Honjo*, Japan; Peter Seeburg, West Germany; David Botstein, USA;
Michael Hunkapiller, USA; Louis Siminovitch, Canada; William R.A. Brown, UK; Nancy A. Jenkins*, USA; Mark H. Skolnick, USA; George F. Cahill,
Jr.*, USA; Y.W. Kan, USA; Ellen Solomon, UK; Mario Capecchi, USA; Lev L. Kisselev, USA; Grant R. Sutherland*, Australia; Webster K. Cavenee*,
Canada; Louis M. Kunkel, USA; Glauco Tocchini-Valentini*, Italy; Walter Gehring, Switzerland; David Patterson, USA; Stylianos E. Antonarakis,
Switzerland; Mark L. Pearson, USA; Norman Arnheim, USA; Georgy P. Georgiev, USSR; Michael Ashburner, UK; Raymond F. Gesteland, USA; Ulf
Pettersson*, Sweden; Walter Gilbert*, USA; Lennart Philipson*, West Germany; Richard Axel, USA; Richard Roberts, USA; Francisco J. Ayala,
USA; Joseph L. Goldstein, USA; David Baltimore, USA; Peter N. Goodfellow, UK; Thomas H. Roderick, USA; Yoram Groner, Israel; Giovanni
Romeo, Italy; Alexander A. Bayev, USSR; Hans-Hilger Ropers, The Netherlands; Arthur L. Beaudet, USA; Frank Grosveld, UK; Paul Berg, USA;
Karl-Heinz Grzeschik*, West Germany; Janet D. Rowley, USA; James F. Gusella, USA; Frank H. Ruddle*, USA; Georgio Bernardi, France;
Yoshiyuki Sakaki, Japan; Adrian Bird, Austria; Nicholas Hastie, UK; Frecerick R. Blattner, USA; Michael Hayden, Canada; Bernard Hirt*,
Switzerland; David Schlessinger, USA; Lars Bolund, Denmark; Charles R. Scriver, Canada; Piet Borst*, The Netherlands; Leroy E. Hood*, USA;
Dirk Bootsma, The Netherlands; David E. Housman, USA; Susan W. Serjeantson, Australia; Peter Humphries, Ireland; Nobuyoshi Shimizu*, Japan;
Sydney Brenner*, UK; Thomas B. Shows*, USA; Roy J. Britten, USA; Yoji Ikawa, Japan; Michael S. Brown, USA; Francois Jacob*, France; Maxine
F. Singer, USA; Alec J. Jeffreys, UK; Marcello Siniscalco, USA; W. Ted Brown, USA; Robert L. Sinsheimer, USA; George Brownlee, UK; Trefor
Jenkins, South Africa; Gail A.P. Bruns, USA; Bertrand Jordan, France; Cassandra Smith, USA; Fotis C. Kafatos*, Greece; Cedric A.B. Smith, UK;
Graham Cameron, West Germany; Oliver Smithies, USA; Howard M. Cann, France; Minoru Kanehisa, Japan; Charles R. Cantor*, USA; Haig
H. Kazazian, Jr., USA; Edwin M. Southern*, UK; Kenneth R. Kidd, USA; Michel Steinmetz, Switzerland; C. Thomas Caskey*, USA; John Silston,
UK; Bruce Cattanach, UK; George Klein*, Sweden; Luca Cavalli-Sforza, USA; Yuji Kohara, UK; Eugene D. Sverdlov, USSR; Raju S. Kucherlapati,
USA; Glenys Thomson, USA; Howard Cedar, Israel; Shirley Tilghman, USA; Pierre Chambon*, France; Peter A. Lalley, USA; Verne M. Chapman,
USA; Jean-Marc Lalouel, USA; Susumu Tonegawa, USA; George Church, USA; Eric Lander, USA; John Tooze*, West Germany; Daniel Cohen,
France; Mark Lathrop, France; Lap-Chee Tsui, Canada; Francis S. Collins*, USA; David H. Ledbetter, USA; Christoper Tyler-Smith, UK; John
Collins, West Germany; Philip Leder, USA; Nguyen Van Cong, France; P. Michael Conneally, USA; Hans Lehrach, UK; Herman van den Berghe,
Belgium; Howard J. Cooke, UK; Leonard S. Lerman, USA; Alex van der Eb, The Netherlands; Andrew Coulson, UK; Peter Little, UK; Marvin van
Dilla, USA; Charles Coutelle, East Germany; Mary Lyon*, UK; Gert Jan van Ommen, The Netherlands; David R. Cox, USA; Jacob V. Maizel, USA;
Akiyoshi Wada, Japan; Diane W. Cox, Canada; Jean-Louis Mandel, France; Douglas C. Wallace, USA; Ian Craig, UK; Tom Maniatis, USA; Dorothy
Warburton, USA; Jean Dausset*, France; Kenichi Matsubara*, Japan; John J. Wasmuth, USA; Kay E. Davies, UK; Allan M. Maxam, USA; James
D. Watson*, USA; Ronald W. Davies, USA; Phyllis J. McAlpine, Canada; David Weatherall*, UK; Muriel Davisson, USA; Victor A. McKusick*,
USA; Robert A. Weinberg, USA; Larry L. Deaven, USA; P. Meera Kahn, The Netherlands; Jean Weissenbach, France; Albert de la Chapelle,
Finland; O.J. Miller, USA; Sherman M. Weissman, USA; Helen Donis-Keller, USA; Andrei D. Mirzabekov*, USSR; Charles Weissmann, Switzerland;
Ford Doolittle, USA; Jan Mohr, Denmark; Raymond L. White, USA; Renato Dulbecco*, USA; Newton Morton, UK; Michael Wigler, USA; John
H. Edwards, UK; Robert Moyzis, USA; Huntington F. Willard, Canada; Argiris Efstratiadis, USA; Daniel Nathans, USA; Robert T. Williamson, UK;
H. John Evans, UK; Susumu Nishimura, Japan; Allan C. Wilson, USA; Marc Fellous, France; S. Numan, Japan; Ernst L. Winnacker, West Germany;
Malcolm A. Ferguson-Smith*, UK; Robert L. Nussbaum, USA; Savio L.C. Woo, USA; Walter Fiers, Belgium; Stephen J. O'Brien, USA; Ronald
G. Worton*, Canada; Uta Francke, USA; Michio Oishi, Japan; Mitsuaki Yoshida, Japan; Jean Frezal*, France; Maynard Olson, USA; Hans
G. Zachau, West Germany; Theodore Friedmann, USA; Stuart H. Orkin, USA; Norton D. Zinder*, USA; Anna-Marie Frischauf, UK; Jurg Ott, USA;
Harald zur Hausen*, West Germany; Antonio Garcia-Bellido, Spain; David C. Page, USA; Tobias Gedde-Dahl, Jr., Norway; Mary Lou Pardue, USA
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South Korea. The current HUGO headquarters office has now ret-
urned back to the United States, in Farmington, Connecticut with a
satellite European office recently moving from London to Newcastle
upon Tyne in the United Kingdom.
There have been 11 presidents of HUGO. Following Victor
McKusick (USA), who was the founding president of HUGO from
1988 to 1991, Walter Bodmer (UK) became the second president of
HUGO from 1991 to 1993. He was followed by Thomas Caskey
(USA) from 1993 to 1995; Grant Sutherland (Australia) from 1996 to
1997; Gert-Jan van Ommen (Netherlands) from 1998 to 1999; Lap-
Chee Tsui (Canada) from 2000 to 2002; Yoshiyuki Sakaki (Japan) from
2002 to 2005; and Leena Peltonen (Finland) from 2005 to 2007. From
2007 to 2012, Edison Liu from the Genome Institute of Singapore led
HUGO, relocating the HUGO headquarters to Singapore. Thereafter,
Stylianos Antonarakis (Switzerland) served as the 10th president of
HUGO from 2012 to 2017. The current president, Charles Lee
(South Korea and USA), started his term in 2017 and continues to lead
HUGO after being re-elected by the executive board members of “the
new HUGO” (Figure 2). Sadly, we recognize the passing of several of
the HUGO past presidents including Victor McKusick in 2008 (Valle &
McKusick, 1921–2008), Leena Peltonen in 2010 (van Ommen, 2010),
and Gert-Jan van Ommen in 2020 (Knoppers & Bovenberg, 2021).
2 | THE ANNUAL HUMAN GENE MAPPING
MEETINGS
Early on, the annual HUGO meetings (Figure 3) were dedicated to
human gene mapping and were referred to as the annual Human Gene
Mapping Meetings (HGMs). Through the 1990s, the HGMs became a
focal point for debate and learning, as the field of Medical Genomics
matured. With the completion of the Human Genome Project, the
HGMs evolved from a small, targeted meeting into a broader scientific
conference for all genetic and genomic researchers with an excellent
platform for participation from industry partners, bio-technology com-
panies, and pharmaceutical giants. Currently, the HGMs comprise a
stimulating program of plenary lectures, symposia, workshops, poster
presentations, satellite meetings, and social events (e.g., gala dinners,
laboratory tours, etc.) and cover a wide range of topics including sys-
tem biology, epigenomics, genomic technologies, drug discovery, gene
therapy, pharmacogenomics, genomic medicine, computational geno-
mics, and bioinformatics.
The HGM2020 meeting was scheduled to be in Perth, Australia
from April 5 to 8, 2020; but due to the COVID-19 pandemic, it even-
tually became the first and only HGM meeting to be conducted fully
virtually (Forrest et al., 2020). Interestingly, there was unprecedented
higher levels of participation from countries such as India, Philippines,
Malaysia, Nigeria, and Sri Lanka due, in large part, to the previous
inaccessibility for scientists from those countries to attend the HGM
meeting. We were reminded that there are many reasons why scien-
tists have difficulties attending scientific meetings in person including
family commitments, time commitments, or lack of funding. Therefore,
to align with HUGO's mission of promoting and supporting fundamen-
tal genomic research throughout the world—including those scientists
from low- and middle-income countries, HUGO will strive to engage
scientists from every nation and provide ways for them to actively
participate in HUGO committees and meetings.
Due to the ongoing pandemic, HGM2021 has now been post-
poned and will occur in person in Tel Aviv on May 23–25, 2022.
Accommodations will be made for scientists to also participate in the
meeting virtually, although challenges still remain with such participa-
tion (e.g., being able to engage in real time with the speakers and
F IGURE 2 The Presidents of HUGO and the years of their service as president
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audience given the time zone differences of different participants). In
addition, there will undoubtedly be some activities (e.g., social events,
etc.) that will have limited effectiveness in a virtual setting, as com-
pared to being in person. Nevertheless, we believe that hybrid models
will be a permanent feature for all future HGM meetings, consistent
with the desires of 85% of those responding to a survey after the
HGM2020 meeting (Forrest et al., 2020).
3 | THE INTERNATIONAL NATURE
OF HUGO
The strength of HUGO has been, and continues to be, its international
focus, particularly for the parts of the world outside of North America
(which is already well represented by the American Society of Human
Genetics—https://www.ashg.org) and Europe (which is already well
represented by the European Society of Human Genetics—https://
www.eshg.org/). More recently, HUGO has particularly served as an
important venue for the gathering of human geneticists from Asian,
South American, and African countries.
To promote this international position of HUGO, two prestigious
international awards were established: the first are the Chen Awards
dedicated to Asian-Pacific scientists and are financially supported by
the Chen Foundation. The Chen Awardees were Li Wen-Hsiung in
2008, Academia Sinica, Taiwan; Yusuke Nakamura in 2010, University
of Tokyo, Japan; Ng Huck Hui in 2010, Genome Institute of Singapore,
Singapore; Yang Huanming in 2011, Beijing Genomics Institute (BGI),
China; Liu Jianjun in 2011, Genome Institute of Singapore, Singapore;
John Mattick in 2012, Garvan Institute of Medical Research, Australia;
Charles Lee in 2012, Bringham and Women's Hospital/Harvard Medi-
cal School, USA; Yoshihide Hayashizaki in 2013, RIKEN, Japan; Patrick
Tan in 2013, Genome Institute of Singapore, Singapore; Edison Liu in
2014, The Jackson Laboratory, USA; Piero Carninci in 2014, RIKEN,
Japan; Jung Wang in 2015, Beijing Genomics Institute (BGI), China;
Bing Ren in 2016, University of California San Diego, USA; Feng Zhang
in 2016, Massachusetts Institute of Technology, USA; Narry Kim in
2017, Seoul National University, South Korea; Aravinda Chakravarti in
2018, Johns Hopkins University, USA; Ami Bhatt in 2018, Stanford
University, USA; Felix Jin Li in 2019, Fudan University, China; Ramanuj
Dasgupta in 2019, Genome Institute of Singapore, Singapore; Anshul
Kundaje in 2019, Stanford University, USA.
The second is the African Prize dedicated to African scientists
working in Africa. This award was introduced in 2015 during the pres-
idency of Stylianos Antonarakis and has been financially supported by
Inqaba Biotechical Industries. The African Prize awardees were Alan
Christoffels in 2015, South African National Bioinformatics Institute
(SANBI), South Africa; Raj Ramesar in 2016, University of Cape Town,
South Africa; Samia Temtamy in 2017, National Research Center
Egypt, Egypt; Collen Masimirembwa in 2018, African Institute of Bio-
medical Science and Technology, Zimbabwe; Christian Happi in 2019,
Redeemer's University and Director of the World Bank funded African
Center of Excellence for Genomics of Infectious Diseases (ACEGID),
Nigeria. Both of these awards have greatly helped in the recognition
of the efforts of scientists working in these areas and provided role
models for regional genomic research with international impact.
3.1 | A new HUGO
Over the last two decades, a variety of other human genome-related
organizations have emerged. Two of these, the Human Genomic Vari-
ation Society (HGVS) and the Human Variome project (HVP) have




Italy; 1999—Brisbane, Australia; 2000—
Vancouver, Canada; 2001—Edinburgh,
Scotland; 2002—Shanghai, China; 2003—
Cancun, Mexico; 2004—Berlin, Germany;
2005—Kyoto, Japan; 2006—Helsinki,
Finland; 2007—Montreal, Canada; 2008—
Hyderabad, India; 2010—Montpellier,
France; 2011—Dubai, UAE; 2012—
Sydney, Australia; 2013—Singapore,
Singapore; 2014—Geneva, Switzerland;
2015—Kuala Lumpur, Malaysia; 2016—
Houston, USA; 2017—Barcelona, Spain;
2018—Yokohama, Japan; 2019—Seoul,
South Korea; 2020—Perth, Australia;
2022—Tel Aviv, Israel (upcoming)
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expanded their communal interests into correctly annotating variants
and gathering clinically relevant genomic variant data at a global scale,
respectively.
3.1.1 | The Human Genome Variation Society
Initially founded by Professor Richard Cotton (Melbourne, Australia)
and a group of HUGO members in 2001, the HGVS has been focused
on accurate naming of genomic variants based on location and effect
in the context of the genome, transcript, and protein. With an expan-
ding understanding of the complexity of genome biology and the
plethora of mechanisms and consequences of variation, HGVS has
kept busy. Their work can be considered in three sections: First, Pro-
fessor Johan den Dunnen (Leiden) has been updating nomenclature to
describe variation as our knowledge of the genome has expanded
exponentially. Their work has succeeded in creating a sustainable sys-
tem that establishes and supports nomenclature standards. Second,
F IGURE 4 The members of the executive board of the new HUGO
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HGVS has organized academic meetings addressing multiple academic
aspects of variant science, especially in the areas of pathogenicity and
interpretation of genetic variants. Third, HGVS has focused on pro-
moting the sharing of genome variation data through the develop-
ment of standards for databases, starting with locus specific mutation
(variant) databases and expanding to national and ethnic variation
databases, disease-centered databases, and others.
3.1.2 | The Human Variome Project
In 2006, the late Richard (Dick) Cotton, built on his experience in
HUGO and HGVS to bring together leaders in genomics, from around
the world, to launch the HVP which aimed to collect, curate, and dis-
tribute all human genetic variation affecting health. Working through
several committees and establishing country nodes and disease- and
gene- specific databases, the HVP became a UNESCO-recognized
non-governmental organization (Burn & Watson, 2016; Kohonen-
Corish et al., 2010). The Leiden Open Variation Database (LOVD),
now in its third version, was developed by Johan den Dunnen and col-
leagues and has always been freely available. As an off-the-shelf data-
base, it enables interested researchers to quickly stand up a database
of gene-specific variants greatly facilitating data sharing (Fokkema
et al., 2005). Following the death of Dick Cotton in 2015, the manage-
ment of the HVP was transferred to the United Kingdom where it has
been supported by an incorporated charity, Global Variome, overseen
by Professors Ingrid Winship, Garry Cutting and John Burn as
trustees. Following the emergence of the Global Alliance for Geno-
mics and Health (GA4GH; https://www.ga4gh.org), the HVP has
focused on maintaining the UNESCO link and supporting two large-
scale international projects: the BRCA challenge—which was devel-
oped in partnership with the GA4GH to catalog and curate the varia-
tion in the BRCA1 and BRCA2 genes, which led to the BRCA
Exchange (Cline et al., 2018) and the Global Globin Network to
address worldwide variation in the alpha- (HBA) and especially beta
globin (HBB) genes and modifiers and their roles in
hemoglobinopathies. This effort is under the leadership of Prof. Raj
Ramesar from South Africa and Prof. Zilfalil bin Alwi from Malaysia.
In 2020, it was agreed to bring HGVS and HVP together with
HUGO to restore the broader base imagined by the HUGO founders.
The members of the executive board of “the new HUGO” (Figure 4)
have now begun to work together to bring these various activities
under one umbrella.
The new HUGO currently comprises seven committees focusing
on: Education, Ethics, Gene and Disease-specific Database Advisory,
International Scientific Advisory, Nomenclature, Journals and Commu-
nication, and Council of Scholars. It is the hope that both Human
Mutation and Human Genomics will become official journals of the
merged organizations.
The ethics committee of HUGO has been well respected for
many years. As advances in genome sciences will undoubtedly con-
tinue to change science and society throughout the world, an orga-
nization that can legitimately democratize the interests and access
of genomic data and technologies throughout the world is of
immense importance. HUGO needs to ensure true international
access to genetic data as well as genomic education, irrespective of
whether a country's limited resources has impeded its ability to con-
tribute its own genomic data.
Another note is the establishment of the new Nomenclature com-
mittee which will report on the efforts of the HGVS nomenclature
committee and the HUGO Gene Nomenclature Committee (HGNC).
The HGVS nomenclature committee had its roots from a mutation/
variant nomenclature committee established at Johns Hopkins and
supported by Victor McKusick (Antonarakis, 1998; Antonarakis &
McKusick, 1994). After the publication of some initial guidelines
(Ad Hoc Committee on Mutation Nomenclature, 1996;
Antonarakis, 1998), a formal nomenclature committee was established
within HGVS under the leadership of Johan den Dunnen, and in 2000,
a comprehensive set of recommendations (den Dunnen &
Antonarakis, 2000) was published which is now known as the HGVS
recommendations/nomenclature (http://www.HGVS.org/varnomen).
These guidelines have gradually acquired worldwide acceptance and
F IGURE 5 Jennifer Lee, Operations Manager
of HUGO (left panel) and Amy McAllister, Project
Coordinator of HUGO (right panel)
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are currently acknowledged as the standard nomenclature in molecu-
lar diagnostics (Gulley et al., 2007; Richards et al., 2015; den Dunnen
et al., 2016). With respect to HGNC originally the Human Gene
Nomenclature Committee (Shows et al., 1979), it was rebranded as
the HUGO Gene Nomenclature Committee following HUGO's estab-
lishment in 1989. It was initially run by Dr. Phyllis J. McAlpine until
1997 and later chaired by Dr. Sue Povey (Povey et al., 2001) until
2007. Currently, HGNC (www.genenames.org) is under the leadership
to Dr. Elspeth Bruford. Housed at the European Bioinformatics Insti-
tute, the work of the HGNC is essential in standardizing gene nomen-
clature for proper literature and database use. Updated HGNC
guidelines (Bruford et al., 2020) and an accompanying editorial were
recently published.
One of the new committees being established is the HUGO
Council of Scholars. The HUGO Council of Scholars is intended to be
comprised of distinguished investigators in genomic sciences as well
as leaders in national/regional genetics and genomics efforts who are
enthusiastic to actively engage in HUGO initiatives and functions.
Scholars will be selected by the HUGO Executive Board and may be
asked to speak at HUGO meetings, advise, or participate in specific
committees, or lead in the writing of key opinion/policy papers
representing HUGO.
4 | CONCLUSIONS
More than 30 years after its inception, to ensure that the benefits of
the Human Genome Project accrue to all the inhabitants of our planet,
HUGO is now reimagined and strengthened by bringing the HGVS
and HVP back into the fold. We have no doubts that Dr. McKusick,
HUGO's founding president, would have been pleased with these
developments and the progress that these collaborative efforts will
bring.
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